Form 4: Genprex CEO Ryan Confer Awarded 45,000 RSUs

Genprex, Inc. CEO Ryan Confer received an award of 45,000 Restricted Stock Units under the company's equity incentive plan, vesting over two years.

Summary

• Ryan M. Confer, President, CEO, CFO, and Director of Genprex, Inc. (GNPX), was granted 45,000 Restricted Stock Units (RSUs).
• The RSUs were awarded on December 22, 2025, under the Genprex, Inc. 2018 Equity Incentive Plan (EIP), as amended and restated effective June 30, 2025.
• The RSUs vest in two installments: 50% on February 27, 2026, and the remaining 50% on February 27, 2027, contingent on continued service.
• Vested RSUs will be paid in shares of Genprex common stock on a one-to-one basis.
• Following this transaction, Ryan M. Confer beneficially owns 45,661 shares of Common Stock.
• The reported beneficial ownership reflects the 1-for-50 reverse stock split of the company's Common Stock, which was effective as of October 21, 2025.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (RSU grant) which is generally viewed as a positive for aligning management and shareholder interests, but it does not contain new operational or financial performance data.

Positives

• The RSU award aligns management's interests with those of shareholders, as the value of the award is tied to the company's stock performance.
• The vesting schedule over two years demonstrates a commitment from the CEO to the company's long-term success.

Negatives

• No direct negatives are presented in this specific Form 4 filing, which primarily reports an executive compensation event.

Risks

• The vesting of the RSUs is contingent upon Ryan M. Confer's continued service as a Service Provider, meaning the award could be forfeited if employment ceases.
• The ultimate value of the RSU award is subject to the future market price of Genprex, Inc. common stock, which carries inherent market risk.

Future Outlook

The RSU award with its multi-year vesting schedule indicates a continued commitment from the CEO to the company's future performance and strategic objectives, aligning his incentives with long-term shareholder value creation.

Industry Context

The granting of Restricted Stock Units (RSUs) to executive officers is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to attract, retain, and incentivize leadership by aligning their financial interests with company performance and shareholder returns.

Comparison to Industry Standards

• Equity-based compensation, such as RSU grants, is a standard practice for executive remuneration across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule of 50% over two years is a typical structure for executive equity awards, aiming to foster long-term commitment and performance.

Corporate Governance

Related Party Transactions

• Ryan M. Confer, President, CEO, CFO, and Director, was granted 45,000 Restricted Stock Units (RSUs) under the company's 2018 Equity Incentive Plan, representing a compensation transaction with a key executive.

Stakeholder Impact

• Shareholders: The RSU grant aligns the CEO's financial incentives with the company's stock performance, potentially benefiting shareholders if the stock value increases.
• Employees: The equity incentive plan provides a framework for attracting and retaining key talent, including executives, which can contribute to overall company stability and growth.

Next Steps

• Ryan M. Confer's continued service as a Service Provider through the vesting dates.
• Vesting of 50% of the RSUs on February 27, 2026.
• Vesting of the remaining 50% of the RSUs on February 27, 2027.

Key Dates

Keywords

Genprex, GNPX, Ryan Confer, Restricted Stock Units, RSU, Equity Incentive Plan, Insider Transaction, Form 4, CEO Compensation, Executive Compensation, Stock Award